Skip to main content
. 2017 Mar 1;4:2054358117695784. doi: 10.1177/2054358117695784

Figure 3.

Figure 3.

Effect of tolvaptan on eGFR (left panel) and TKV (right panel) by CKD stage in the TEMPO 3:4 trial.

Source. Republished from Torres et al63 with permission of the American Society of Nephrology; permission conveyed through Copyright Clearance Center, Inc.

Note. eGFR = estimated glomerular filtration rate; TKV = total kidney volume; CKD = chronic kidney disease.